Agonist‐dependent differential effects of berberine in human platelet aggregation

Shah, Bukhtiar H.; Nawaz, Zafar; Saeed, Sheikh A.; Gilani, A.H.

doi:10.1002/(sici)1099-1573(1998)12:1+<s60::aid-ptr251>3.0.co;2-j

Cited by 11 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to the cholesterol and triglyceridelow ering effects, berberine could also exert other relevant activities in cardiovascular disease prevention. In fact, berberine inhibits platelet aggregation interfering selec tively with the collagenmediated adhesion process [29] and could therefore be synergic with the antiplatelet ac tivity shown by policosanol [30]. Berberine inhibits also the production of lysophosphatidylcholineinduced re active oxygen species and the ERK1/2 pathway in vas cular smooth muscle cells, important cofactors in the pathogenesis of the atherosclerotic plaques [31].…”

Section: Discussionmentioning

confidence: 99%

Eulipidemic Effects of Berberine Administered Alone or in Combination with Other Natural Cholesterol-lowering Agents

Cicero

Rovati²,

Setnikar³

2011

Arzneimittelforschung

View full text Add to dashboard Cite

Berberine (BERB) and a combination (COMB) of berberine (CAS 2086-83-1) with policosanol (CAS 557-61-9), red yeast extract (containing monacolin, CAS 557-61-9), folic acid and astaxanthin were orally administered daily for 4 weeks to 40 subjects with moderate dyslipidemias divided in two parallel groups each of 20 subjects. Total cholesterol (TC), LDL, HDL, Non HDL, ApoB, ApoA, Lp(a) and triglycerides (TG) were measured before and at the end of treatments. BERB and COMB significantly reduced TC (respectively by 16% and 20%), LDL (by 20% and 25%), ApoB (by 15% and 29%) and TG (by 22% and 26%), and increased HDL (by 6.6% and 5.1%). Adverse events or impairments of liver transaminases or of CPK were not observed. In conclusion, food supplements containing natural products such as berberine, policosanol, red yeast extracts, folic acid and astaxanthin could be a useful support to diet and life style changes to correct dyslipidemias and to reduce cardiovascular risk in subjects with moderate mixed dyslipidemias.

show abstract

Section: Discussionmentioning

confidence: 99%

Eulipidemic Effects of Berberine Administered Alone or in Combination with Other Natural Cholesterol-lowering Agents

Cicero

Rovati²,

Setnikar³

2011

Arzneimittelforschung

View full text Add to dashboard Cite

show abstract

“…The plant's root extract was found to reduce oxidative stress. A signi icant impact was also seen when the plant's aqueous and methanolic extract was tested against CCl4-induced liver damage [28].…”

Section: Antioxidantmentioning

confidence: 99%

Test

2023

Int. J.Exp. Biomed. Res.

View full text Add to dashboard Cite

show abstract

“…BBR chloride also inhibited platelet activation via down-regulation of P-selectin expression and inhibiting fibrinogen binding to platelet GP IIb/IIIa integrin receptor on the surface of platelets 100. Shah et al 101 reported that BBR inhibited collagen-induced platelet aggregation without affecting the platelet responses to the other platelet agonists including platelet-activating factor (PAF), AA and adrenaline. Its anti-platelet activity has been suggested to be exerted via suppressing with the collagen-induced adhesion process without any effect on cAMP, or A23187-induced platelet aggregation 101.…”

Section: Bbr In the Treatment Of Cardiovascular Diseasesmentioning

confidence: 99%

“…Shah et al 101 reported that BBR inhibited collagen-induced platelet aggregation without affecting the platelet responses to the other platelet agonists including platelet-activating factor (PAF), AA and adrenaline. Its anti-platelet activity has been suggested to be exerted via suppressing with the collagen-induced adhesion process without any effect on cAMP, or A23187-induced platelet aggregation 101. While in one animal study investigating the effect of BBR on GPVI (glycoprotein receptor for collagen, expressed in platelets) BBR could not statistically inhibit the expression of GPVI 102, another study has proven the protective effects of BBR in combination with ligustrazine (alkylpyrazine from Ligusticum chuanxiong ) in a rat model of coronary microembolization 103.…”

Section: Bbr In the Treatment Of Cardiovascular Diseasesmentioning

confidence: 99%

Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics

et al. 2019

View full text Add to dashboard Cite

Cardiovascular and metabolic diseases (CVMD) are the leading causes of death worldwide, underscoring the urgent necessity to develop new pharmacotherapies. Berberine (BBR) is an eminent component of traditional Chinese and Ayurvedic medicine for more than 2000 years. Recently, BBR has attracted much interest for its pharmacological actions in treating and/or managing CVMD. Recent discoveries of basic, translational and clinical studies have identified many novel molecular targets of BBR (such as AMPK, SIRT1, LDLR, PCSK9, and PTP1B) and provided novel evidences supporting the promising therapeutic potential of BBR to combat CVMD. Thus, this review provides a timely overview of the pharmacological properties and therapeutic application of BBR in CVMD, and underlines recent pharmacological advances which validate BBR as a promising lead drug against CVMD.

show abstract

Agonist‐dependent differential effects of berberine in human platelet aggregation

Cited by 11 publications

References 0 publications

Eulipidemic Effects of Berberine Administered Alone or in Combination with Other Natural Cholesterol-lowering Agents

Eulipidemic Effects of Berberine Administered Alone or in Combination with Other Natural Cholesterol-lowering Agents

Test

Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics

Contact Info

Product

Resources

About